House dust mite allergy immunotherapy - Bial
Alternative Names: 1-day polymerized depot Allergovac; Allergovac DPT; Allergovac house dust mite; Allergovac house dust mite depot; BIA 15-2957; Polymerized depot allergovac - Bial; V01AALatest Information Update: 02 Oct 2021
At a glance
- Originator Bial
- Developer BIAL
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic rhinoconjunctivitis
Most Recent Events
- 01 Sep 2017 Roxall Medicina Espana completes a phase I trial for Allergic rhinoconjunctivitis in Spain (SC) (NCT02881879)
- 10 Apr 2017 Bial Industrial Farmacéutica terminates phase II trial in Allergic rhinoconjunctivitis in Spain (EudraCT2016-002944-18)
- 14 Nov 2016 BIAL Industrial Farmaceutca initiates a phase II trial for Allergic rhinoconjunctivitis in Spain (EudraCT2016-002944-18)